GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anterogen Co Ltd (XKRX:065660) » Definitions » Capital Expenditure

Anterogen Co (XKRX:065660) Capital Expenditure : ₩-5.97 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Anterogen Co Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Anterogen Co's cash flow for capital expenditures for the three months ended in Mar. 2024 was ₩-6 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-5.97 Mil.

Anterogen Co Capital Expenditure Historical Data

The historical data trend for Anterogen Co's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anterogen Co Capital Expenditure Chart

Anterogen Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,017.91 -5,736.40 -3,539.62 -1,480.81 -203.28

Anterogen Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.08 - - - -5.97

Anterogen Co Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-5.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anterogen Co (XKRX:065660) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anterogen Co Ltd (XKRX:065660) » Definitions » Capital Expenditure
Comparable Companies
XKRX:261780 XKRX:348150 XKRX:365270 XKRX:388870 XKRX:348080 XKRX:166480 XKRX:203400 XKRX:234690 XKRX:353810 XKRX:389030 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Namsung Plaza, Gasan-dong, 405, 130, Digital-ro, Geumcheon-gu, Seoul, KOR, 08589
Website
http://www.anterogen.com
Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.

Anterogen Co (XKRX:065660) Headlines

No Headlines